prolactinoma

Summary

Summary: A pituitary adenoma which secretes PROLACTIN, leading to HYPERPROLACTINEMIA. Clinical manifestations include AMENORRHEA; GALACTORRHEA; IMPOTENCE; HEADACHE; visual disturbances; and CEREBROSPINAL FLUID RHINORRHEA.

Top Publications

  1. ncbi Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists
    D Kojo Hamilton
    Department of Neurosurgery, University of Virginia, Charlottesville, USA
    Pituitary 8:53-60. 2005
  2. ncbi Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up
    Gerald Raverot
    Institut National de la Sante et de la Recherche Medicale, Unité 842, Universite de Lyon, Lyon 1, Unité Mixte de Recherche UMR S842, Faculté de médecine Lyon Est, F 69372 Lyon, Cedex 08, France
    J Clin Endocrinol Metab 95:1708-16. 2010
  3. ncbi Advances in the treatment of prolactinomas
    Mary P Gillam
    Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
    Endocr Rev 27:485-534. 2006
  4. ncbi Giant prolactinomas: clinical management and long-term follow up
    Raj K Shrivastava
    Department of Neurosurgery, Mount Sinai Medical Center, New York, New York 10029, USA
    J Neurosurg 97:299-306. 2002
  5. ncbi Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients
    J Kreutzer
    Department of Neurosurgery, University of Erlangen Nuremberg, Schwabachanlage 6, 91054 Erlangen, Germany
    Eur J Endocrinol 158:11-8. 2008
  6. ncbi Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy
    Katarina Berinder
    Department of Molecular Medicine and Surgery, Endocrine and Diabetes Unit, Karolinska Institutet, 171 76, Stockholm, Sweden
    Pituitary 14:199-207. 2011
  7. pmc Thrombospondin-1 (TSP-1) analogs ABT-510 and ABT-898 inhibit prolactinoma growth and recover active pituitary transforming growth factor-β1 (TGF-β1)
    M Victoria Recouvreux
    Instituto de Biología y Medicina Experimental Consejo Nacional de Investigaciones Científicas y Técnicas, Vuelta de Obligado 2490, Buenos Aires 1428, Argentina
    Endocrinology 153:3861-71. 2012
  8. ncbi Issues in flow and oxygenation dependent contrast (FLOOD) imaging of tumours
    F A Howe
    CRC Biomedical Magnetic Resonance Research Group, Department of Biochemistry and Immunology, St George s Hospital Medical School, London SW17 ORE, UK
    NMR Biomed 14:497-506. 2001
  9. ncbi Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up
    A Colao
    Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica, Universita Federico II di Napoli, Naples, Italy
    J Clin Endocrinol Metab 83:2777-80. 1998
  10. ncbi Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men
    Ilan Shimon
    Institute of Endocrinology and Metabolism, Rabin Medical Center, Beilinson Hospital, Petah Tiqwa, Israel
    Eur J Endocrinol 156:225-31. 2007

Research Grants

  1. PITUITARY-SPECIFIC ONCOGENE SIGNALING MECHANISMS
    Arthur Gutierrez Hartmann; Fiscal Year: 2009
  2. REGULATION OF PROLACTIN SECRETION AT THE LACTOTROPH
    JOEL TABAK-SZNAJDER; Fiscal Year: 2013
  3. PITUITARY TUMORS--PATHOGENESIS AND CELLULAR FUNCTION
    THOMAS CROXTON; Fiscal Year: 1993
  4. HUMAN PROLACTINOMAS
    AMBER OCHOA; Fiscal Year: 1999
  5. FETAL ALCOHOL EXPOSURE AND TUMORIGENESIS
    Zehava Gottesfeld; Fiscal Year: 1990
  6. Attenuation of Estrogen-Induced Cell Proliferation
    DOUGLAS WENDELL; Fiscal Year: 2003
  7. ROLE OF OPIATES IN ALCOHOL-INDUCED NEUROTOXICITY
    DIPAK SARKAR; Fiscal Year: 2009
  8. Biology of the NK cell cytolytic activity rhythm
    DIPAK KUMAR SARKAR; Fiscal Year: 2010
  9. Fetal Alcohol Effects on Circadian clocks and POMC
    DIPAK KUMAR SARKAR; Fiscal Year: 2010
  10. ESTROGEN MITOGENIC ACTION IN THE PITUITARY
    DIPAK SARKAR; Fiscal Year: 2003

Detail Information

Publications233 found, 100 shown here

  1. ncbi Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists
    D Kojo Hamilton
    Department of Neurosurgery, University of Virginia, Charlottesville, USA
    Pituitary 8:53-60. 2005
    Surgery for prolactinoma patients is usually reserved for those who are intolerant of or have an inadequate response to medication. We report the results of surgical treatment in these patients.
  2. ncbi Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up
    Gerald Raverot
    Institut National de la Sante et de la Recherche Medicale, Unité 842, Universite de Lyon, Lyon 1, Unité Mixte de Recherche UMR S842, Faculté de médecine Lyon Est, F 69372 Lyon, Cedex 08, France
    J Clin Endocrinol Metab 95:1708-16. 2010
    ..Predicting pituitary tumor behavior remains a challenge. This multiparameter investigation aimed to identify markers for recurrence and progression in prolactin tumors...
  3. ncbi Advances in the treatment of prolactinomas
    Mary P Gillam
    Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
    Endocr Rev 27:485-534. 2006
    ....
  4. ncbi Giant prolactinomas: clinical management and long-term follow up
    Raj K Shrivastava
    Department of Neurosurgery, Mount Sinai Medical Center, New York, New York 10029, USA
    J Neurosurg 97:299-306. 2002
    ..Giant prolactinomas are rare tumors whose treatment and outcome has only been addressed in isolated case reports. The authors document the long-term follow-up findings and clinical outcome in a group of patients with giant prolactinomas...
  5. ncbi Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients
    J Kreutzer
    Department of Neurosurgery, University of Erlangen Nuremberg, Schwabachanlage 6, 91054 Erlangen, Germany
    Eur J Endocrinol 158:11-8. 2008
    ..Classical' surgical indications are intolerance or lack of efficiency of DA therapy. Focusing on a possible shift of recent indications, we retrospectively analyzed our results of surgical treatment in prolactinomas...
  6. ncbi Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy
    Katarina Berinder
    Department of Molecular Medicine and Surgery, Endocrine and Diabetes Unit, Karolinska Institutet, 171 76, Stockholm, Sweden
    Pituitary 14:199-207. 2011
    ..85, P = 0.034). In conclusion, beneficial metabolic changes were seen in prolactinoma patients after treatment with DA agonists, underscoring the importance of an active treatment approach and to ..
  7. pmc Thrombospondin-1 (TSP-1) analogs ABT-510 and ABT-898 inhibit prolactinoma growth and recover active pituitary transforming growth factor-β1 (TGF-β1)
    M Victoria Recouvreux
    Instituto de Biología y Medicina Experimental Consejo Nacional de Investigaciones Científicas y Técnicas, Vuelta de Obligado 2490, Buenos Aires 1428, Argentina
    Endocrinology 153:3861-71. 2012
    ..These results place these synthetic TSP-1 analogs as potential alternative or complementary treatments in dopamine agonist-resistant prolactinomas...
  8. ncbi Issues in flow and oxygenation dependent contrast (FLOOD) imaging of tumours
    F A Howe
    CRC Biomedical Magnetic Resonance Research Group, Department of Biochemistry and Immunology, St George s Hospital Medical School, London SW17 ORE, UK
    NMR Biomed 14:497-506. 2001
    ..We have measured the R(2)* changes in a prolactinoma tumour model for a variety of vasoactive challenges [carbogen, 100% oxygen and 100% nitrogen as different ..
  9. ncbi Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up
    A Colao
    Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica, Universita Federico II di Napoli, Naples, Italy
    J Clin Endocrinol Metab 83:2777-80. 1998
    ..we report the clinical presentation, response to medical treatment, and long-term follow-up of 26 patients with prolactinoma (15 macro- and 11 micro-adenomas) diagnosed at the age of 7-17 yr...
  10. ncbi Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men
    Ilan Shimon
    Institute of Endocrinology and Metabolism, Rabin Medical Center, Beilinson Hospital, Petah Tiqwa, Israel
    Eur J Endocrinol 156:225-31. 2007
    ..To review our experience with cabergoline, a D2-selective dopamine agonist, for the treatment of giant prolactinomas...
  11. ncbi Clinical practice. Prolactinoma
    Janet A Schlechte
    Department of Internal Medicine, University of Iowa, Iowa City, USA
    N Engl J Med 349:2035-41. 2003
  12. ncbi BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists
    Cintia M Dos Santos Silva
    Division of Endocrinology, Hospital Universitário Clementino Fraga Filho Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
    Obesity (Silver Spring) 19:800-5. 2011
    ..objectives of this study were to determine the prevalence of obesity, overweight, MS, and IR in patients with prolactinoma before and after therapy with DA and to evaluate the relation between prolactin (PRL), body weight, fat ..
  13. ncbi Multiple endocrine neoplasia type 1 variant with frequent prolactinoma and rare gastrinoma
    Wei Hao
    Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Clin Endocrinol Metab 89:3776-84. 2004
    ..Results in cases from two kindreds were that 93% showed parathyroid adenoma, 40% pituitary tumor (always prolactinoma), and 27% enteropancreatic endocrine tumor...
  14. ncbi High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium
    Adrian F Daly
    Department of Endocrinology, Centre Hospitalier Universitaire de Liege, Domaine Universitaire du Sart Tilman, 4000 Liege, Belgium
    J Clin Endocrinol Metab 91:4769-75. 2006
    ..Prevalence data are important for assessing the burden of disease on the health care system; data on pituitary adenoma prevalence are very scarce...
  15. pmc Efficacy and safety of cabergoline as first line treatment for invasive giant prolactinoma
    Eun Hee Cho
    Division of Endocrinology and Metabolism, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
    J Korean Med Sci 24:874-8. 2009
    Although cabergoline is effective in the treatment of micro- and macro-prolactinoma, little is known about its efficacy in the treatment of invasive giant prolactinoma...
  16. ncbi Screening for macroprolactinaemia and pituitary imaging studies
    Omar M Hauache
    Department of Endocrinology, Fleury Diagnostic Center, Sao Paulo, Brazil
    Clin Endocrinol (Oxf) 57:327-31. 2002
    ....
  17. pmc Management of psychosis associated with a prolactinoma: case report and review of the literature
    Shirin Ali
    McLean Hospital, Boston, MA, USA
    Psychosomatics 51:370-6. 2010
    ..Psychosis is treated with dopamine-receptor blockers that may result in elevated serum prolactin and symptomatic hyperprolactinemia...
  18. ncbi Discrimination of prolactinoma from hyperprolactinemic non-functioning adenoma
    Jae Won Hong
    Department of Internal Medicine, Institute of Endocrinology, Yonsei University College of Medicine, 250 Seongsanno, Seodaemun gu, Seoul 120 752, Korea
    Endocrine 37:140-7. 2010
    The objective of this study was to evaluate characteristics that discriminate prolactinoma from non-functioning pituitary macroadenoma with hyperprolactinemia. We included 117 patients with hyperprolactinemic pituitary macroadenomas...
  19. ncbi Successful monotherapy treatment with aripiprazole in a patient with schizophrenia and prolactinoma
    Bradley Freeman
    University of South Florida College of Medicine, Tampa, FL, USA
    J Psychiatr Pract 13:120-4. 2007
  20. ncbi A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report
    Mineko Murakami
    Department of Neurosurgery, Teikyo University Chiba Medical Center, Ichihara City, Chiba, Japan
    Neurosurgery 68:E1761-7; discussion E1767. 2011
    The case presented here describes the clinical evolution of a pituitary carcinoma from an atypical prolactinoma after temozolomide (TMZ) treatment. The mechanism of acquisition of TMZ resistance was analyzed.
  21. ncbi Clinical and laboratory features greatly overlap in patients with macroprolactinemia or monomeric hyperprolactinemia
    L Vilar
    Division of Endocrinology, Hospital das Clinicas, Federal University of Pernambuco, Recife, Brazil
    Minerva Endocrinol 32:79-86. 2007
    ..The aim of this study was to evaluate the clinical and laboratory features of 64 patients with macroprolactinemia and to compare them to those of individuals with monomeric hyperprolactinemia...
  22. pmc CEBPD suppresses prolactin expression and prolactinoma cell proliferation
    Yunguang Tong
    Academic Affairs, Los Angeles, California 90048, USA
    Mol Endocrinol 25:1880-91. 2011
    ..CEBPD expression levels are decreased approximately 7-fold in experimental rat prolactinoma cells...
  23. ncbi The effect of aripiprazole and quinagolide, a dopamine agonist, in a patient with symptomatic pituitary prolactinoma and chronic psychosis
    Rosalie Broekhof
    Department of Psychiatry, Leiden University Medical Center, P O Box 9600, 2300RC, Leiden, The Netherlands
    Gen Hosp Psychiatry 34:209.e1-3. 2012
    ..Conversely, drugs for the treatment of prolactinoma may activate dopamine D2 receptors, which can induce or aggravate psychosis...
  24. ncbi Prevalence of pituitary adenomas in macroprolactinemic patients may be higher than it is presumed
    Gonca Tamer
    Department of Internal Medicine, Istanbul Faculty of Medicine, University of Istanbul, Telli Kavak sok No 8, Topbas sitesi, A Blok, D 24 Erenkoy, 34738, Istanbul, Turkey
    Endocrine 41:138-43. 2012
    ..048). Prevalence of pituitary adenomas in macroprolactinemic patients is lower compared with the true hyperprolactinemic patients, but may be higher than that found in other recent studies and in the general population...
  25. ncbi Malignant prolactinoma: case report and review of the literature
    Marleen Kars
    Department of Endocrinology, Leiden University Medical Center, Albinusdreef 2, PO Box 9600, 2300 RC Leiden, The Netherlands
    Eur J Endocrinol 155:523-34. 2006
    ..In addition, we reviewed all available literature on published cases of malignant prolactinoma and detailed their epidemiological, clinical, and histopathological characteristics...
  26. ncbi Metastatic prolactinoma presenting as a cervical spinal cord tumour in multiple endocrine neoplasia type one (MEN-1)
    Michelle V Gordon
    Clin Endocrinol (Oxf) 66:150-2. 2007
  27. pmc Progression on metastatic neuroendocrine carcinoma from a recurrent prolactinoma: a case report
    M Sironi
    Department of Pathology, Legnano General Hospital, Legnano, Milano, Italy
    J Clin Pathol 55:148-51. 2002
    ..The patient was known in the department because of previous multiple surgery for a locally invasive pituitary prolactinoma (eight years, three years, and one year previously)...
  28. ncbi Incidence of pituitary tumors in the human population of Croatia
    Milan Vrkljan
    Center for Clinical Neuroendocrinology and Pituitary Diseases, Department of Endocrinology, Diabetes and Metabolic Diseases, University Hospital Sestre Milosrdnice, University of Zagreb, Zagreb, Croatia
    Coll Antropol 30:157-61. 2006
    ..The patient's classification is based on regional (Mediterranean and continental region, 20 counties) and the state level. In our analysis we haven't found difference in incidence of tumors between Mediterranean and continental region...
  29. ncbi Giant invasive pituitary prolactinoma with falsely low serum prolactin: the significance of 'hook effect'
    Maria Fleseriu
    Department of Endocrinology, Diabetes and Metabolism, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Neurooncol 79:41-3. 2006
    ..His prolactin was found to be 13,144 ng/ml in our lab after surgery confirming the diagnosis of invasive giant prolactinoma. The patient developed a complete right third, fourth and sixth nerve palsy postoperatively...
  30. ncbi Gene expression study of thyrotropin releasing hormone (TRH) receptor using RT-PCR: relationship to clinical and immunohistochemical phenotypes in a series of human pituitary adenomas
    Junko Igarashi-Migitaka
    Department of Anatomy, St Marianna University School of Medicine, Sugao, Kawasaki 216 8511, Japan
    Endocr J 50:459-67. 2003
    ..It should be noted that the PRL response to TRH in prolactinoma or an abnormal response of gonadotropin and/or its subunits to TRH in gonadotroph cell adenomas is considered ..
  31. ncbi The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type
    Paweł Bolko
    Department of Endocrinology, Internal Diseases and Metabolism, Karol Marcinkowski University of Medical Sciences, Poznan, Poland
    Pol Arch Med Wewn 109:489-95. 2003
    b>Prolactinoma is the most frequent type of secreting pituitary tumours. In the treatment, pharmacotherapy with dopamine agonists is considered the first-line option...
  32. ncbi Prolactin and prostate hypertrophy: a pilot observational, prospective, case-control study in men with prolactinoma
    Annamaria Colao
    Department of Clinical and Molecular Endocrinology and Oncology, University Federico II of Naples, 80131 Naples, Italy
    J Clin Endocrinol Metab 89:2770-5. 2004
    ..prostate enlargement in humans, we designed this open, prospective, case-control study enrolling 20 men with prolactinoma (aged 34 +/- 10 yr) and 20 age-matched healthy men...
  33. ncbi The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma
    Mary P Gillam
    Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University, The Feinberg Medical School, Chicago, Illinois 60611, USA
    J Clin Endocrinol Metab 87:4447-51. 2002
    ..Ultimately, further reduction in PRL on this therapy permitted endogenous testosterone production. Thus, novel pharmacological maneuvers may permit successful medical treatment of some patients with invasive macroprolactinomas...
  34. ncbi Pharmacologic resistance in prolactinoma patients
    Mark E Molitch
    Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University Feinberg School of Medicine, 303 E Chicago Avenue, Tarry 15 731, Chicago, IL 60611, USA
    Pituitary 8:43-52. 2005
    ..Reduction of endogenous estrogen, use of selective estrogen receptor modulators, and aromatase inhibitors are potential experimental approaches...
  35. ncbi First reported pediatric case of systemic lupus erythematosus associated with prolactinoma
    Peter D Reuman
    Pediatric Rheumatology and Clinical Research, Children s Hospital Medical Center, One Perkins Square, Akron, OH 44308, USA
    Arthritis Rheum 50:3616-8. 2004
    ..We present the first reported pediatric case of prolactinoma associated with SLE, in a 13-year-old white female...
  36. ncbi Endocrinological outcome following first time transsphenoidal surgery for GH-, ACTH-, and PRL-secreting pituitary adenomas
    R A Kristof
    Department of Neurosurgery, University of Bonn, Bonn, Germany
    Acta Neurochir (Wien) 144:555-61; discussion 561. 2002
    ..To study remission rates and pituitary functions following transsphenoidal surgery of newly diagnosed GH-, ACTH-, and PRL-secreting pituitary adenomas...
  37. ncbi A case of postprandial cluster-like headache with prolactinoma: dramatic response to cabergoline
    Kiyoshi Negoro
    Headache 45:604-6. 2005
    ..Magnetic resonance images showed a pituitary tumor. Just after starting treatment with cabergoline, the headaches resolved completely and the patient has been absolutely free from such headache attacks for 2 years...
  38. ncbi Pathological changes after radiotherapy for primary pituitary carcinoma: a case report
    Hideomi Yamashita
    Department of Radiology, University of Tokyo Hospital, 7 3 1, Hongo, Bunnkyou ku, Tokyo 113 8655, Japan
    J Neurooncol 75:209-14. 2005
    ..We confirmed that necrosis but no apoptosis were coexistent in the cells post irradiation for pituitary carcinoma...
  39. ncbi Headache induced by dopamine agonists prescribed for prolactinoma: think SUNCT!
    A J Larner
    Walton Centre for Neurology and Neurosurgery, Fazakerley, Liverpool, UK
    Int J Clin Pract 60:360-1. 2006
    ..neuralgiform headache with conjunctival injection and tearing (SUNCT) syndrome may be associated with pituitary prolactinoma and may be induced by treatment of prolactinoma with dopamine agonists...
  40. ncbi Cabergoline treatment of pregnant women with macroprolactinomas
    M Laloi-Michelin
    AP HP, Hopital Lariboisiere, Service de médecine interne B, Paris, France
    Int J Gynaecol Obstet 99:61-2. 2007
  41. ncbi Body fat in nonobese women with prolactinoma treated with dopamine agonists
    Erika C O Naliato
    Division of Endocrinology, Department of Internal Medicine, Federal University of Rio de Janeiro, Hyperprolactinemia Unit, Clementino Fraga Filho University Hospital, Rio de Janeiro, Brazil
    Clin Endocrinol (Oxf) 67:845-52. 2007
    To evaluate body fat in nonobese women with prolactinoma treated with dopamine agonists, using whole body dual energy X-ray absorptiometry (DXA) and to correlate DXA results with biochemical data and clinical aspects of the prolactinoma.
  42. ncbi Prolactinoma in some Ménière's patients--is stress involved?
    Kathleen C Horner
    Laboratoire d Otologie, Hopital Nord, Marseille, France
    Neuropsychopharmacology 26:135-8. 2002
    ..The presence of prolactinoma was confirmed by MRI in six cases out of six investigated and the others have not yet been followed up in this ..
  43. ncbi Psoriasis in association with prolactinoma: three cases
    M Sánchez Regaña
    Department of Dermatology, Hospital Sagrado Corazon, University of Barcelona, C París 83 87 5th floor, 08029 Barcelona, Spain
    Br J Dermatol 143:864-7. 2000
    ..psoriasis in whom increase in severity and extent of the skin lesions correlated with the development of a prolactinoma. In all three patients, administration of bromocriptine, a dopamine agonist that suppresses the secretion of ..
  44. ncbi Tumor tissue identification in the pseudocapsule of pituitary adenoma: should the pseudocapsule be removed for total resection of pituitary adenoma?
    Eun Jig Lee
    Division of Endocrinology, Pituitary Tumor Clinic, Yonsei University College of Medicine, Seoul, Korea
    Neurosurgery 64:ons62-9; discussion ons69-70. 2009
    ..We investigated the precise histology of the pseudocapsule. Furthermore, we evaluated the remission rate, the changes in pituitary function, and the recurrence rate after intensive resection of the pseudocapsule...
  45. ncbi Effects of estrogen receptor antagonist on biological behavior and expression of growth factors in the prolactinoma MMQ cell line
    Hongtao Lv
    Beijing Neurosurgical Institute, Capital Medical University, 6 Tiantan Xili, Chongwen District, Beijing, 100050, People s Republic of China
    J Neurooncol 102:237-45. 2011
    The relationship between estrogen and pituitary prolactinoma is well documented. The biological effects of estrogen are mainly mediated by estrogen receptor α (ERα)...
  46. ncbi Attenuated expression of menin and p27 (Kip1) in an aggressive case of multiple endocrine neoplasia type 1 (MEN1) associated with an atypical prolactinoma and a malignant pancreatic endocrine tumor
    Emi Ishida
    Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Maebashi, Japan
    Endocr J 58:287-96. 2011
    ..We describe the case of a 56 year-old male with an atypical prolactinoma and malignant pancreatic neuroenocrine tumor...
  47. ncbi [Cabergoline-induced tension pneumocephalus in a patient with giant invasive prolactinoma. Case report]
    J Castro-Castro
    Servicios de Neurocirugía, Complejo Hospitalario de Ourense, Ourense, Espana
    Neurocirugia (Astur) 22:558-61; discussion 561. 2011
    ..He had been treated for 2 weeks with cabergoline after an invasive prolactinoma was discovered...
  48. ncbi Polycystic ovary syndrome and prolactinoma association
    Irfan Yavasoglu
    Adnan Menderes University Medical Faculty, Aydin, Turkey
    Intern Med 48:611-3. 2009
    ..with irregular menses, obesity, hirsutism and infertility, and hyperprolactinemia who was diagnosed as PCOS and prolactinoma and admitted to our clinic. Prolactinoma and PCOS association is a rare condition...
  49. pmc An Intronic mutation is associated with prolactinoma in a young boy, decreased penetrance in his large family, and variable effects on MEN1 mRNA and protein
    L Drori-Herishanu
    Section of Endocrinology and Genetics, Program on Developmental Endocrinology Genetics PDEGEN, NIH, Bethesda, Maryland 20892, USA
    Horm Metab Res 41:630-4. 2009
    Prolactinomas are rare tumors in prepubertal children. A prolactinoma in a young child may be due to sequence variants in genes that are known to cause these tumors ( MEN1, PRKAR1A, AIP)...
  50. ncbi Effects of different levels of hypercapnic hyperoxia on tumour R(2)* and arterial blood gases
    S P Robinson
    CRC Biomedical Magnetic Resonance Research Group, Division of Biochemistry and Immunology, St George s Hospital Medical School, London, UK
    Magn Reson Imaging 19:161-6. 2001
    ..The data support the concept that levels of hypercapnia can be reduced without loss of enhanced oxygenation and hence potential radiotherapeutic benefit...
  51. ncbi A novel use of temozolomide in a patient with malignant prolactinoma
    Stephen Byrne
    Department of Neurosurgery, Flinders Medical Centre, Flinders Drive, Bedford Park, South Australia 5042, Australia
    J Clin Neurosci 16:1694-6. 2009
    ..who presented to our department in 2007 with bitemporal hemianopia secondary to a large recurrent pituitary prolactinoma in the sellar region and metastatic deposits elsewhere in his neuraxis...
  52. ncbi Use of the Leksell gamma knife in the treatment of prolactinoma patients
    Jana Jezkova
    Third Department of Medicine, First Medical Faculty, Charles University, Prague, Czech Republic
    Clin Endocrinol (Oxf) 70:732-41. 2009
    ..Surgical and radiation treatment is also indicated in certain situations. We describe our 12-year experience in treating prolactinomas with the Leksell gamma knife (LGK)...
  53. ncbi Successful treatment of a large macroprolactinoma with cabergoline during pregnancy
    C Liu
    Department of Medicine, University of California, San Francisco, 94143 0326, USA
    Pituitary 4:179-85. 2001
    ..A 7 week pregnant woman with a history of a prolactinoma presented to the endocrine clinic with the complaints of headaches and nausea...
  54. ncbi Latent prolactinoma on MRI-selective venous sampling and trans-sphenoidal microsurgical treatment
    H Nakagawa
    Department of Neurosurgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Japan
    Neurol Res 23:691-6. 2001
    ..a correspondence of laterality of the peak prolactin level with the main tumor location in patients with latent prolactinoma. However, the tumor/nontumor ratio did not necessarily coincide with the pattern of tumor location, and tumor ..
  55. ncbi Prolactinoma in children and adolescents
    H L Fideleff
    Endocrinology Unit, Department of Medicine, Hospital T Alvarez, Buenos Aires, Argentina
    Horm Res 72:197-205. 2009
    ..The diagnosis of prolactinoma requires both radiographic evidence of pituitary adenoma and laboratory analysis documenting the presence of ..
  56. ncbi Pituitary tumours: the prolactinoma
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Via S Pansini 5, 80131 Naples, Italy
    Best Pract Res Clin Endocrinol Metab 23:575-96. 2009
    ..The patients achieving disappearance of the tumours and suppression of PRL levels during treatment are those showing the highest likelihood to have persistent remission of hyperprolactinaemia after treatment withdrawal...
  57. ncbi Hyperprolactinemia: different clinical expression in childhood
    L Saranac
    Pediatric Clinic, University Clinical Center, Nis, Serbia endoljilja yahoo com
    Horm Res Paediatr 73:187-92. 2010
    ..Hyperprolactinemia is the most common disturbance in pituitary gland secretion. Functional diversity of prolactin action is responsible for different initial clinical expressions of hyperprolactinemia...
  58. ncbi Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma
    Marleen Kars
    Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, P O Box 9600, 2300 RC Leiden, The Netherlands
    J Clin Endocrinol Metab 93:3348-56. 2008
    ..The aim of the present study was to assess the prevalence of valvular heart disease in patients treated with dopamine agonists for prolactinomas...
  59. ncbi Giant prolactinomas in men: efficacy of cabergoline treatment
    S M Corsello
    Institute of Endocrinology, Catholic University School of Medicine, Rome, Italy
    Clin Endocrinol (Oxf) 58:662-70. 2003
    The term 'giant prolactinoma' can be used for tumours larger than 4 cm in diameter and/or with massive extrasellar extension...
  60. ncbi Efficacy of cabergoline on rapid escalation of dose in men with macroprolactinomas
    A Bhansali
    Departments of Endocrinology, Postgraduate Institute of Medical Education and Research Chandigarh, India
    Indian J Med Res 131:530-5. 2010
    ..This possibly results in delayed normalization of serum prolactin and slow reduction in tumour size. This study was planned to assess the efficacy and safety of rapid escalation of cabergoline doses in men with macroprolactinomas...
  61. ncbi Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline
    Shlomo Melmed
    Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    J Clin Endocrinol Metab 96:273-88. 2011
    ..The aim was to formulate practice guidelines for the diagnosis and treatment of hyperprolactinemia...
  62. ncbi Pituitary abscess associated with prolactinoma
    Awadhesh Kumar Jaiswal
    Department of Neurosurgery, Neurosciences Centre, All India Institute of Medical Sciences, New Delhi 110029, India
    J Clin Neurosci 11:533-4. 2004
    ..She had an uneventful postoperative recovery. At 2 years follow up, she was doing well...
  63. pmc Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists
    Muriel Babey
    Department of Neurosurgery, University of Berne, Inselspital, 3010, Berne, Switzerland
    Pituitary 14:222-30. 2011
    ..guidelines recommend long-term dopamine agonist (DA) therapy as a first-line approach to the treatment of small prolactinoma, some patients continue to prefer a primary surgical approach...
  64. ncbi SUNCT syndrome in two patients with prolactinomas and bromocriptine-induced attacks
    H Massiou
    Department of Neurology, Hospital Lariboisiere, 2 rue Ambroise Pare, 75475 Paris Cedex 10, France
    Neurology 58:1698-9. 2002
  65. ncbi Bone density in women with prolactinoma treated with dopamine agonists
    Erika Cesar de Oliveira Naliato
    Division of Endocrinology, Department of Internal Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
    Pituitary 11:21-8. 2008
    1) to evaluate bone density in women with prolactinoma treated with dopamine agonists and healthy controls, using dual energy x-ray absorptiometry (DXA), (2) to classify the results according to the current International Society for ..
  66. ncbi Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists
    Lisa M Neff
    Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Tufts New England Medical Center, Boston, MA 02111, USA
    Pituitary 10:81-6. 2007
    ..In this report, we describe a patient with an invasive prolactinoma resistant to conventional therapy that responded to the administration of the alkylating agent, temozolomide.
  67. ncbi Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Via S Pansini 5, 80131 Napoli, Italy
    J Clin Endocrinol Metab 93:3777-84. 2008
    ..Cabergoline, a dopamine receptor-2 agonist used to treat prolactinomas, was associated with increased risk of cardiac valve disease in Parkinson's disease...
  68. ncbi Quality of life is decreased in female patients treated for microprolactinoma
    M Kars
    Department of Endocrinology and Metabolic Diseases, C4 R, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands
    Eur J Endocrinol 157:133-9. 2007
    ..We evaluated this topic in female patients with microprolactinoma, because other pituitary adenomas are associated with decreased quality of life...
  69. ncbi Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required
    M Kars
    Department of Endocrinology and Metabolic Diseases, C4 R, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands
    Eur J Endocrinol 159:363-7. 2008
    ..the safety of treatment with ergot-derived dopamine agonists in patients with endocrine diseases, especially prolactinoma. Six cross-sectional studies have been published recently, of which five studies do not show an association ..
  70. ncbi Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas
    Felipe F Casanueva
    Department of Medicine, Endocrine Division, Santiago de Compostela University, Spain
    Clin Endocrinol (Oxf) 65:265-73. 2006
    ....
  71. ncbi Clinical profile and long term follow up of children and adolescents with prolactinomas
    Shrikrishna V Acharya
    K E M Hospital, Parel, Mumbai, 400012 Maharashtra, India
    Pituitary 12:186-9. 2009
    ..presentation, response to medical treatment, and long-term follow-up of 39 children and adolescents with prolactinoma (F:M; 30:9) (30 macro and 9 microadenoma) diagnosed at the age of 9-20 years...
  72. pmc Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy
    J Kharlip
    Division of Endocrinology and Metabolism, Johns Hopkins University School of Medicine, Baltimore, Maryland 21201, USA
    J Clin Endocrinol Metab 94:2428-36. 2009
    ..Recurrence of hyperprolactinemia after cabergoline withdrawal ranges widely from 36 to 80%. The Pituitary Society recommends withdrawal of cabergoline in selected patients...
  73. ncbi Long-term outcome of patients with macroprolactinomas initially treated with dopamine agonists
    Marleen Kars
    Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, The Netherlands
    Eur J Intern Med 20:387-93. 2009
    ..Dopamine agonists are the first line therapy for the treatment of prolactinomas. The aim of this study was to assess the outcome of macroprolactinomas during long-term follow-up after initial treatment with dopamine agonists...
  74. ncbi Prolactinomas and pregnancy
    Marcello Delano Bronstein
    Neuroendocrine Unit, Division of Endocrinology and Metabolism, Hospital das Clinicas, University of S Paulo Medical School, Av 9 de Julho 3858, 01406 100, S Paulo, SP, Brazil
    Pituitary 8:31-8. 2005
    ..Reintroduction of bromocriptine in such cases can lead to tumor reduction and clinical improvement. Surgery can also be employed as treatment for symptomatic tumor growth in pregnancy...
  75. ncbi Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis
    Olaf M Dekkers
    Department of Endocrinology and Metabolic Diseases, C4 R, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands
    J Clin Endocrinol Metab 95:43-51. 2010
    ..Dopamine agonists are the treatment of choice for prolactinomas and symptomatic idiopathic hyperprolactinemia. However, the optimal treatment strategy and treatment duration is not clear in all details...
  76. ncbi Prolactinomas, dopamine agonists and headache: two case reports
    M J Levy
    Headache Group, Institute of Neurology, London, UK
    Eur J Neurol 10:169-73. 2003
    ..We present two cases of prolactinoma-associated headache...
  77. ncbi Predictive value of serum prolactin levels measured immediately after transsphenoidal surgery
    Arun P Amar
    Department of Neurosurgery, Keck School of Medicine, University of Southern California, Los Angeles, USA
    J Neurosurg 97:307-14. 2002
    ....
  78. ncbi Headache associated with pituitary adenomas
    T Abe
    Department of Neurosurgery, Showa University School of Medicine, 5-8 Hatanodal 1, Shinagawa-ku, Tokyo 142-8666, Japan
    Headache 38:782-6. 1998
    ..1%) of 7 patients did not always contribute to headache. The headache was improved after surgery in 14 (73.6%) of the 19 patients. In the male patients who survived postoperatively (5 of 6), headache was improved...
  79. ncbi Resolution of migraine following bromocriptine treatment of a prolactinoma (pituitary microadenoma)
    N Hartman
    UCLA Department of Psychiatry, USA
    Headache 35:430-1. 1995
    ..Treatment of the prolactinoma with bromocriptine provided complete and lasting resolution of the migraine as well, suggesting a possible ..
  80. ncbi Common ancestral mutation in the MEN1 gene is likely responsible for the prolactinoma variant of MEN1 (MEN1Burin) in four kindreds from Newfoundland
    S E Olufemi
    Laboratory of Gene Transfer, National Human Genome Research Institute, NIH, Bethesda, Maryland 20892 4442, USA
    Hum Mutat 11:264-9. 1998
    ..5 Mb region. A nonsense mutation in the MEN1 gene has been found to be responsible for the disease in the affected members in all four of the MEN1Burin families, providing convincing evidence of a common founder...
  81. ncbi Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma
    S Cannavo
    Cattedra di Endocrinologia, Universita di Messina, Italy
    J Endocrinol Invest 22:354-9. 1999
    ..In conclusion, this study confirms the effectiveness and safety of CAB for patients with PRL-secreting pituitary adenoma and suggests that it can be considered a first choice treatment...
  82. ncbi Relapse of hyperprolactinemia after transsphenoidal surgery for microprolactinoma: lessons from long-term follow-up
    John A Thomson
    University Department of Medicine, Glasgow Royal Infirmary, Glasgow, Scotland G4 0SF, UK
    Neurosurgery 50:36-9; discussion 39-40. 2002
    ..The long-term results of transsphenoidal surgery for microprolactinoma, with particular reference to the question of permanence of relapse of hyperprolactinemia after biochemical cure, are examined...
  83. ncbi Endoscopic approach to the pituitary lesions: contemporary method and review of the literature
    A Kuroki
    Department of Neurosurgery, Yamagata University School of Medicine, 2 2 2 Iida nishi, Yamagata 990 9585, Japan
    Biomed Pharmacother 56:158s-164s. 2002
    ..The overall result by endoscopic transsphenoidal surgery is as good as or better than that by the traditional microscopic transsphenoidal surgery...
  84. ncbi Clusterlike headache as first manifestation of a prolactinoma
    J Porta-Etessam
    Department of Neurology, Hospital Universitario 12 de Octubre, Madrid, Spain
    Headache 41:723-5. 2001
    ..Symptomatic cluster headache should be suspected when the clinical features of the headache are atypical. By inducing vascular mechanisms, the parasellar lesion may have played a role in initiating the cluster headache...
  85. pmc SUNCT syndrome secondary to prolactinoma
    M S Matharu
    Headache Group, Institute of Neurology The National Hospital for Neurology and Neurosurgery, Queen Square, London, UK
    J Neurol Neurosurg Psychiatry 74:1590-2. 2003
    ..We report a case of SUNCT syndrome secondary to a prolactinoma. Administration of dopamine agonists led to complete resolution of the SUNCT attacks...
  86. ncbi Evolution of an aggressive prolactinoma into a growth hormone secreting pituitary tumor coincident with GNAS gene mutation
    Andrea G Lania
    Endocrinology and Diabetology Unit, Department of Medical Sciences, Fondazione Ospedale Maggiore Istituto di Ricovero e Cura a Carattere Scientifico, University of Milan, 20122 Milan, Italy
    J Clin Endocrinol Metab 95:13-7. 2010
    ..Conversely, the occurrence of a prolactinoma evolving into clinically and biochemically active acromegaly is a rare phenomenon.
  87. ncbi Nerve growth factor regulates dopamine D(2) receptor expression in prolactinoma cell lines via p75(NGFR)-mediated activation of nuclear factor-kappaB
    Chiara Fiorentini
    Division of Pharmacology, Department of Biomedical Sciences and Biotechnology, University of Brescia, 25123 Brescia, Italy
    Mol Endocrinol 16:353-66. 2002
    Two groups of prolactinoma cell lines were identified...
  88. ncbi Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas
    M Biswas
    Department of Endocrinology, University Hospital of Wales, Heath Park, Cardiff, Wales, UK
    Clin Endocrinol (Oxf) 63:26-31. 2005
    ..Subjects received dopamine agonist (DA) therapy with either cabergoline or bromocriptine for a period of 2 to 3 years in the majority of cases, followed by a trial of treatment withdrawal...
  89. ncbi Multiple endocrine neoplasia type 1
    Gerard M Doherty
    NW Thompson Professor of Surgery, University of Michigan, Ann Arbor, Michigan, USA
    J Surg Oncol 89:143-50. 2005
    ..Care of people with MEN-1 requires knowledge of the problems that may arise, and the best approaches to detect and care for the manifestations of this incurable, but manageable, disease...
  90. ncbi Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas
    X Zhang
    Cedars Sinai Research Institute University of California School of Medicine, Los Angeles 90048, USA
    J Clin Endocrinol Metab 84:761-7. 1999
    ..The ubiquitous and prevalent expression of pituitary adenoma PTTG suggests that PTTG plays a role in pituitary tumorigenesis and invasiveness...
  91. ncbi Can radiation induce pituitary tumors? Giant prolactinoma after radiation exposure
    Nilesh S Kurwale
    Cardio Neuro Centre, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110 029, India
    J Clin Neurosci 15:1287-8. 2008
    ..The role of radiation exposure in the etiology of pituitary adenoma is discussed, along with a literature review of radiation-induced tumors...
  92. ncbi Cabergoline therapy for prolactinomas: is valvular heart disease a real safety concern?
    Sophie Vallette
    Department of Endocrinology, Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, 1560 Sherbrooke East, Montreal, QC, H2L 4M1, Canada
    Expert Rev Cardiovasc Ther 8:49-54. 2010
    ..The clinical significance of the present findings has yet to be confirmed by future larger prospective studies with rigorous echocardiographic protocols and prolonged duration of follow-up...
  93. pmc Single dose of the antivascular agent, ZD6126 (N-acetylcolchinol-O-phosphate), reduces perfusion for at least 96 hours in the GH3 prolactinoma rat tumor model
    Dominick J O McIntyre
    Department of Basic Medical Sciences, St George s Hospital Medical School, Tooting, London, UK
    Neoplasia 6:150-7. 2004
    ..This study investigated the duration of the response to the vascular targeting agent, ZD6126, of the GH3 prolactinoma, in which efficacy and dose-response have previously been demonstrated...
  94. ncbi Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Section of Endocrinology, Federico II University of Naples, Naples, Italy
    N Engl J Med 349:2023-33. 2003
    ..We performed an observational, prospective study of cabergoline (a dopamine-receptor agonist) withdrawal in such patients...
  95. ncbi Late development of intraventricular papillary pituitary carcinoma after irradiation of prolactinoma
    Martha Lilia Tena-Suck
    Department of Neuropathology, National Institute of Neurology and Neurosurgery, Manuel Velasco Suarez, Delegación Tlalpan CP 14269, Mexico City, Mexico
    Surg Neurol 66:527-33; discussion 533. 2006
    ..Most of the cases have been reported as metastases from pituitary carcinoma. A case of papillary pituitary carcinoma developed 12 years after radiotherapy for prolactin-secreting hormone pituitary adenoma is presented...
  96. ncbi Dopaminergic D2 receptor knockout mouse: an animal model of prolactinoma
    Carolina Cristina
    Instituto de Biologia y Medicina Experimental CONICET, Vuelta de Obligado 1490, 1428 Buenos Aires, Argentina
    Front Horm Res 35:50-63. 2006
    ..The D2R knockout mouse represents a unique animal model to study dopamine-resistant prolactinomas, and VEGF-A may be an alternative therapeutic target in this pathology...
  97. ncbi Cortistatin-17 and somatostatin-14 display the same effects on growth hormone, prolactin, and insulin secretion in patients with acromegaly or prolactinoma
    S Grottoli
    Division of Endocrinology and Metabolism, Department of Internal Medicine, San Giovanni Battista Molinette Hospital, Corso Dogliotti 14, 10126 Turin, Italy
    J Clin Endocrinol Metab 91:1595-9. 2006
    ..Cortistatin binds all somatostatin receptor subtypes but also has particular central actions; moreover, a specific cortistatin receptor has also been discovered...
  98. ncbi Three-dimensional imaging of hormone-secreting cells and their microvessel environment in estrogen-induced prolactinoma of the rat pituitary gland by confocal laser scanning microscopy
    J Itoh
    Laboratories for Structure and Function Research, Tokai University, School of Medicine, Isehara, Kanagawa, Japan
    Appl Immunohistochem Mol Morphol 9:364-70. 2001
    ..three-dimensional imaging of hormone-secreting cells and their microvascular environment in estrogen-induced prolactinoma of the rat pituitary gland...
  99. ncbi Metastatic prolactinoma: case report with immunohistochemical assessment for p53 and Ki-67 antigens
    Paulo S Crusius
    Institute of Neurology and Neurosurgery, Passo Fundo, RS, Brazil
    Arq Neuropsiquiatr 63:864-9. 2005
    ..In conclusion, p53 staining is not positive in all pituitary carcinomas. A high Ki-67 proliferative index in a pituitary adenoma might indicate a more aggressive behavior...
  100. ncbi Nonsurgical cerebrospinal fluid rhinorrhea in invasive macroprolactinoma: incidence, radiological, and clinicopathological features
    S G I Suliman
    Department of Endocrinology, Oxford Centre for Diabetes, Endocrinology, and Metabolism, Churchill Hospital, Oxford OX3 7LJ, United Kingdom
    J Clin Endocrinol Metab 92:3829-35. 2007
    ..Macroprolactinomas (MPRLs) may result in nonsurgical (spontaneous or dopamine agonist induced) cerebrospinal fluid (CSF) rhinorrhea; however, the incidence of and mechanisms underlying this phenomenon are poorly understood...
  101. ncbi Malignant prolactinoma with multiple bone and pulmonary metastases. Case report
    Cristina Lamas
    Department of Endocrinology, Hospital Universitario Puerta de Hierro, Madrid, Spain
    J Neurosurg 101:116-21. 2004
    ..The authors describe a 14-year-old boy who presented with visual loss caused by a pituitary prolactinoma. He underwent transsphenoidal surgery, radiotherapy, and dopamine agonist therapy, but 6 years after the ..

Research Grants22

  1. PITUITARY-SPECIFIC ONCOGENE SIGNALING MECHANISMS
    Arthur Gutierrez Hartmann; Fiscal Year: 2009
    ..we propose to move our Ras work to a more translational level, and address the role of Ras/MAPK in pituitary prolactinoma tumor formation, and whether PTTG-1 and Menin act as downstream effectors in this pathway...
  2. REGULATION OF PROLACTIN SECRETION AT THE LACTOTROPH
    JOEL TABAK-SZNAJDER; Fiscal Year: 2013
    ..For example, the benign hypersecreting pituitary tumor known as a prolactinoma is treated with the dopamine agonists bromocryptine or cabergoline...
  3. PITUITARY TUMORS--PATHOGENESIS AND CELLULAR FUNCTION
    THOMAS CROXTON; Fiscal Year: 1993
    ..of prolactin (PRL) a common cause of female infertility, is usually associated with an anterior pituitary prolactinoma. This study will characterize changes in the physiological mechanisms controlling PRL secretion that occur with ..
  4. HUMAN PROLACTINOMAS
    AMBER OCHOA; Fiscal Year: 1999
    ..We recently identified two distinct cell populations in human prolactinoma cell cultures. The majority of cells are lactotrophs, as evident by their expression and release of prolactin...
  5. FETAL ALCOHOL EXPOSURE AND TUMORIGENESIS
    Zehava Gottesfeld; Fiscal Year: 1990
    ..which were exposed to alcohol in utero display increased susceptibility to estrogen-induced pituitary tumors (prolactinoma) and a further enhancement of immune suppression...
  6. Attenuation of Estrogen-Induced Cell Proliferation
    DOUGLAS WENDELL; Fiscal Year: 2003
    ..Consequently, estrogen treatment of F344 rats induces uncontrolled cell proliferation and prolactinoma. Aim #1 of this project is to develop a primary cell culture system to investigate the effect of the BN allele ..
  7. ROLE OF OPIATES IN ALCOHOL-INDUCED NEUROTOXICITY
    DIPAK SARKAR; Fiscal Year: 2009
    ....
  8. Biology of the NK cell cytolytic activity rhythm
    DIPAK KUMAR SARKAR; Fiscal Year: 2010
    ..The proposed series of studies should enhance our knowledge of the physiological mechanisms orchestrating NK cell circadian function. ..
  9. Fetal Alcohol Effects on Circadian clocks and POMC
    DIPAK KUMAR SARKAR; Fiscal Year: 2010
    ..This information should help to develop therapeutic strategies in managing sleep-wake disturbances and the resultant health consequences in FAE offspring. ..
  10. ESTROGEN MITOGENIC ACTION IN THE PITUITARY
    DIPAK SARKAR; Fiscal Year: 2003
    ..Such knowledge should be important in understanding prolactinoma because increased proliferation is an early step in cell transformation.
  11. OPIOID AND ALCOHOL REGULATED IMMUNE FUNCTION
    DIPAK SARKAR; Fiscal Year: 2002
    ....
  12. CONSTRUCTION OF BIOLOGY RESEARCH FACILITY
    DIPAK SARKAR; Fiscal Year: 2002
    ..abstract_text> ..
  13. Outcome Measures in Idiopathic Intracranial Hypertension
    Deborah Friedman; Fiscal Year: 2008
    ..Acquire the training, mentoring and experience necessary to conduct independent, funded clinical research in ophthalmologic and neurological disorders Obtain a Masters Degree in Public Health/Clinical Investigator track ..
  14. Carney Complex: A Model for PKA-Mediated Tumorigenesis
    LAWRENCE KIRSCHNER; Fiscal Year: 2008
    ..abstract_text> ..
  15. Creation of a mouse model of isolated GH deficiency
    Roberto Salvatori; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  16. Optical imaging of epilepsy in rat and human neocortex
    THEODORE SCHWARTZ; Fiscal Year: 2007
    ..These experiments will set the groundwork for implementing optical recordings in general clinical practice as a novel technique for mapping and predicting human seizures. ..
  17. Consequences of lifetime isolated Growth Hormone deficiency
    Roberto Salvatori; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  18. Consequences of generalized lack of GHRH
    Roberto Salvatori; Fiscal Year: 2005
    ..By recombinase technique, we will generate KO lines with no Neor, avoiding any interference with distant or neighboring genes. In addition, results obtained in the GHRHKO1 line will be confirmed or disproved. ..
  19. ROLE OF THE CNC GENE IN DEVELOPMENT AND TUMORIGENESIS
    LAWRENCE KIRSCHNER; Fiscal Year: 2004
    ..The long-term goal of this project is to identify the role that the CNC gene product plays in the normal development of the endocrine and other systems, as well as the role that the mutated gene plays in tumorigenesis. ..
  20. Molecular analysis of GHRH receptor missense mutations
    Roberto Salvatori; Fiscal Year: 2004
    ..Altogether, these experiments will teach us new information about the pathophysiology of GHRHR signaling in health and disease. ..
  21. ESTROGEN ACTION IN THE PITUITARY
    Margaret Shupnik; Fiscal Year: 2005
    ..These studies will provide important information on mechanisms for positive and negative E feedback at the cellular level. ..